1
Clinical Trials associated with Pn-MAPS30plus / Active, not recruitingPhase 1 A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of An Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.
100 Clinical Results associated with Pn-MAPS30plus
100 Translational Medicine associated with Pn-MAPS30plus
100 Patents (Medical) associated with Pn-MAPS30plus
100 Deals associated with Pn-MAPS30plus